Home > Gastroenterology > Nivolumab with chemo may be new first-line option for stomach cancer

Nivolumab with chemo may be new first-line option for stomach cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Oncology
Reuters Health - 20/01/2022 - Adding nivolumab to oxaliplatin-based chemotherapy significantly improves progression-free survival (PFS) in patients with untreated, HER2-negative, unresectable advanced or recurrent gastric or gastroesophageal-junction cancer, according to results of the ATTRACTION-4 study.  The combination "could potentially be a new first-line treatment option" in this patient population, researchers write in The Lancet Oncology.  The study enrolled 724 treatment-naive patients (regardless of PD-L1 expression) from centers in Japan, South Korea and Taiwan. Patients received chemotherapy every three weeks (intravenous oxaliplatin 130 mg/m2 on da...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on